etoposide and busulfan
etoposide has been researched along with busulfan in 203 studies
Research
Studies (203)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 8 (3.94) | 18.7374 |
1990's | 59 (29.06) | 18.2507 |
2000's | 59 (29.06) | 29.6817 |
2010's | 60 (29.56) | 24.3611 |
2020's | 17 (8.37) | 2.80 |
Authors
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Barbusca, E; Cannizzo, G; Cascioferro, S; Daidone, G; Maggio, B; Mancuso, S; Plescia, F; Raffa, D; Raimondi, MV; Tolomeo, M | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Copelan, EA | 1 |
Bocheńska, J; Glejzer, O; Jaźwiec, B; Klimczak, A; Kołodziej, J; Pacuszko, T; Sedzimirska, M; Tomaszewska-Toporska, B; Tomeczko, J; Was, A | 1 |
Masauji, N; Matsue, K; Tohi, T; Tsukuda, K | 1 |
Ortlieb, ML; Parkerson, SG; Spitzer, T; Zerbe, MB | 1 |
Ambros, P; Emminger, W; Emminger-Schmidmeier, W; Ferstl, G; Fink, FM; Haas, OA; Höcker, P; Mann, G; Peters, C; Urban, C | 1 |
Mandelli, F; Meloni, G | 1 |
Bierman, PJ; Dennison, JD; Gordon, BG; Klassen, L; Kumar, PP; McGuire, TR; Reed, EC; Sanger, WG; Vaughan, WP; Warkentin, PI | 1 |
Emminger, W; Emminger-Schmidmeier, W; Gadner, H; Peters, C | 1 |
Bloom, EJ; Buck, DS; Przepiorka, D; Rosenfeld, CS; Schwinghammer, TL; Shadduck, RK | 1 |
Jones, RJ; Santos, GW | 1 |
Fleischhauer, D; Gassmann, W; Loeffler, H; Müller-Ruchholtz, W; Uharek, L; Wottge, HU | 1 |
Cahill, R; Cottler-Fox, M; Deeg, HJ; Greenspan, A; Lynch, M; Spitzer, TR; Torrisi, J | 1 |
Gassmann, W; Löffler, H; Mueller-Ruchholtz, W; Schmitz, N; Uharek, L; Wottge, HU | 1 |
Blume, KG; Forman, SJ | 1 |
Jacobs, P | 1 |
Grospietsch, G; Hinney, B; Knappe, G; Kühnle, H; Rümelin, B; Temme, D | 1 |
Hodel, C; Zschauer, A | 1 |
Asai, T; Asanuma, K; Hiruma, K; Kashimura, M; Nakamura, H; Oh, H; Saito, H; Yoshida, S | 1 |
Bullorsky, EO; Ceresetto, JM; Pest, P; Peters, RA; Shanley, CM; Stemmelin, GR | 1 |
Crowther, D; Ghielmini, M; Morgenstern, GR; Pettengell, R; Radford, JA; Scheid, C; Stern, PL | 1 |
Bernstein, E; Brodsky, I; Bulova, S; Crilley, P; Marks, DI; Mullaney, R; Resnick, K; Styler, MJ; Topolsky, D | 1 |
Andersson, BS; Bellare, N; Gajewski, JL; Giralt, SA; Khouri, IF; McCarthy, P; Mehra, R; Nath, R; Przepiorka, D; van Besien, KW | 1 |
Bout, M; Brémond, JL; Dayan, A; Delain, M; Domenech, J; Gihana, E; Linassier, C; Petit, A; Petitdidier, C; Truglio, D | 1 |
Duława, J; Franek, E; Hołowiecki, J; Kokot, F; Markiewicz, M; Wacławik, A; Wiecek, A; Wojnar, J | 1 |
Ashihara, E; Fujita, N; Goto, H; Hirata, T; Inaba, T; Nakagawa, M; Okawa, K; Oku, N; Shimazaki, C; Yamagata, N | 1 |
Bélanger, R; Boileau, J; Bonny, Y; Gyger, M; Kassis, J; Lacombe, M; Lavallée, R; Perreault, C; Roy, DC; von Bueltzingsloewen, A | 1 |
Adler, SS; Feingold, JM; Ghalie, R; Kaizer, H; Korenblit, AD; Manson, S; Pruett, J; Reynolds, J; Valentino, LA | 1 |
Bewermeier, P; Hossfeld, DK; Krüger, W; Mross, K; Reifke, J; Stockschläder, M; Zander, A | 1 |
Bewermeier, P; Hossfeld, DK; Krüger, W; Mross, K; Stockschläder, M; Zander, A | 1 |
Fujioka, K; Funabiki, T; Ikuta, K; Kai, S; Kajigaya, Y; Matsuyama, S; Sakai, H; Sekiguchi, H; Sumita, H; Takahashi, H | 1 |
Cahill, R; Deeg, HJ; Gadner, H; Ortlieb, M; Peters, C; Spitzer, TR; Tefft, MC; Torrisi, J; Urban, C | 1 |
Kabisch, H; Kalhs, P; Krüger, W; Lechner, K; Peters, S; Stockschläder, M; Zander, A; Zeller, W | 1 |
Damon, LE; Linker, CA; Ries, CA; Rugo, HS; Wolf, JL | 3 |
Bulova, SI; Ciobanu, N; Cooper, BW; Creger, RJ; Crilley, P; Fox, RM; Gucalp, R; Lazarus, H; Shina, DC; Topolsky, D | 1 |
Tutschka, PJ | 1 |
Amylon, MD; Blume, KG; Chao, NJ; Forman, SJ; Long, GD; Negrin, RS; Stein, AS; Wong, RM | 1 |
Appelbaum, FR; Blume, KG; Forman, SJ; Henslee-Downey, JP; Kopecky, KJ; LeMaistre, CF; Stiff, PJ | 1 |
Ikeda, H; Inoue, T; Masaoka, T; Murayama, S; Ohtani, M; Shibata, H; Song, C; Tang, JT; Teshima, T; Yamazaki, H | 1 |
Köpf-Maier, P; Sass, G | 1 |
Bettoni, C; Daszkiewicz, P; Ebell, W; Głuszak, B; Kaczmarek-Kanold, M; Lange, A; Malicki, J; Suchnicki, K; Wachowiak, J | 1 |
Elfenbein, GJ; Fields, KK; Moscinski, LC; Perkins, JB | 1 |
Akiyama, H; Kanda, Y; Onozawa, Y; Sakamaki, H; Sasaki, T; Takamoto, S; Tanikawa, S | 1 |
Crowther, D; Deakin, DP; Harris, M; Morgenstern, GR; Pettengell, R; Radford, JA; Ryder, D; Scarffe, JH; Wilkinson, PM; Woll, PJ | 1 |
Andrews, F; Bolwell, B; Collins, R; Fay, J; LeFever, A; Levitt, D; List, A; Nemunaitis, J; Pallansch, P; Resta, D; Rosenfeld, CS; Schuster, MW; Taylor, R | 1 |
Davidson, TG; Devine, SM; Dix, SP; Geller, RB; Gilmore, CE; Heffner, LT; Hillyer, CD; Holland, HK; Jerkunica, I; Lin, LS; Mullins, RE; Saral, R; Wingard, JR; Winton, EF; York, RC | 1 |
Bandini, G; Belardinelli, A; Fiacchini, M; Geromin, A; Gherlinzoni, F; Manfroi, S; Mangianti, S; Miggiano, MC; Motta, MR; Ricci, P; Rizzi, S; Rosti, G; Testoni, N; Tura, S; Visani, G | 1 |
Chiusolo, P; Di Mario, A; Leone, G; Micciulli, G; Salutari, P; Sica, S; Tommasi, M | 1 |
Agaliotis, DP; Ballester, OF; Elfenbein, GJ; Fields, KK; Goldstein, SC; Hiemenz, JW; Janssen, WE; Perkins, JB; Zorksy, PE | 1 |
Appelbaum, FR; Bensinger, WI; Buckner, CD; Chauncey, T; Demirer, T; Fefer, A; Lilleby, K; Petersen, FB; Rowley, S; Sanders, J; Storb, R | 1 |
Avalos, BR; Bechtel, TP; Belt, PS; Copelan, EA; Elder, PJ; Ezzone, SA; Hehmeyer, DM; Penza, SL; Scholl, MD | 1 |
Bewermeier, P; Hossfeld, DK; Kruger, W; Mross, K; Reifke, J; Zander, A | 1 |
Abella, E; Adams, PT; al-Katib, A; Dragovic, J; Du, W; Janakiraman, N; Karanes, C; Raman, SB; Ratanatharathorn, V; Sensenbrenner, L; Silver, SM; Uberti, J; Varterasian, M | 1 |
Kortmann, RD | 1 |
Akashi, K; Eto, T; Fujisaki, T; Gondo, H; Harada, M; Harada, N; Hayashi, S; Hirota, Y; Kinukawa, N; Makino, S; Matsuishi, E; Miyamoto, T; Mizuno, S; Murakawa, M; Nagafuji, K; Niho, Y; Ohno, Y; Okamura, T; Shibuya, T; Takamatsu, Y; Takenaka, K; Taniguchi, S; Tanimoto, K; Teshima, T; Yamasaki, K | 1 |
Becker, AT; Gruppo, RA; Harris, RE; Hashmi, R; Morris, CL; Morris, JD; Sambrano, JE | 1 |
Buckner, CD; Rhinehart, S; Schwartzberg, L; Weaver, CH; West, J; West, WH; Zhen, B | 1 |
Badri, N; Boogaerts, M; Carella, AM; Dabouz-Harrouche, F; Gautier, L; Gorin, NC; Lennard, A; Link, H; Simonsson, B; Tomas-Martinez, JF | 1 |
Boqué, C; Grañena, A | 1 |
de Wit, M; Erttmann, R; Hänel, M; Hoffknecht, M; Kabisch, H; Kröger, N; Krüger, W; Stockschläder, M; Weh, HJ; Zander, AR; Zeller, W | 1 |
Fukuda, H; Kunitoh, H; Saijo, N; Sekine, I | 1 |
Bogusławska-Jaworska, J; Gorczyńska, E; Słociak, M; Toporski, J | 1 |
Berger, C; Braumann, D; de Witt, M; Erttmann, R; Fiedler, W; Grimm, J; Horstmann, M; Hossfeld, KD; Illiger, HJ; Kabisch, H; Kröger, N; Krüger, W; Kuse, R; Schönrock, P; Stockshläder, M; Weh, HJ; Zander, AR; Zeller, W | 1 |
Curti, A; Lemoli, RM; Leopardi, G; Motta, MR; Rizzi, S; Testoni, N; Tura, S; Visani, G | 1 |
Alvarez Román, MT; Canales Albendea, MA; Hernández Navarro, F; Villanueva Pavón, R | 1 |
Bella, S; Burnelli, R; Garaventa, A; Locatelli, F; Melchionda, F; Paolucci, G; Pession, A; Prete, A | 1 |
Brodsky, I; Case, D; Crilley, P; Damon, LE; Linker, CA; Navarro, W; Ries, CA; Rubin, A; Rugo, HS; Sayre, P; Topolsky, D; Wolfe, JL; Zamkoff, K | 1 |
Berger, HM; Dürken, M; Finckh, B; Fischer, R; Herrnring, C; Kohlschütter, A; Kohlschütter, B; Moison, RM; Nagel, S; Nielsen, P; Pichlmeier, U; Zander, AR | 1 |
Bergman, GF; Blumberg, JB; Carlson, JL; Furr, CE; Galloway, JR; Griffith, DP; Jonas, CR; Jones, DP; Puckett, AB; Szeszycki, EE; Tyre, C; Ziegler, TR | 1 |
Andresen, SW; Avalos, BR; Bechtel, TP; Bolwell, BJ; Copelan, EA; Elder, PJ; Ezzone, SA; Goormastic, M; Kalaycio, M; O'Donnell, LC; Penza, SL; Pohlman, B; Risley, GL; Scholl, MD; Tighe, MB; Young, DC | 1 |
Coppes, MJ; Gamis, A; Hagg, R; Kamani, N; Mustafa, MM; Sandler, ES; Wall, D | 1 |
Braumann, D; Colberg, H; del Valle, F; Erttmann, R; Fiedler, W; Finkenstein, F; Holstein, K; Kabisch, H; Kröger, N; Krüger, W; Kuse, R; Mayer, U; Metzner, B; Renges, H; Sonnen, R; Sonnenberg, S; Stute, N; Zabelina, T; Zander, AR | 1 |
Bondiau, PY; Foa, C; Magné, N; Otto, J; Thyss, A | 1 |
Beijnen, JH; Mathôt, RA; Schellens, JH; van den Bongard, HJ | 1 |
Goh, YT; Hwang, YK; Linn, YC; Tan, CH; Tan, HC | 1 |
Bilgrami, S; Bona, RD; Clive, J; Edwards, RL; Fox, J; Furlong, F; Kazierad, D; Naqvi, BH; Tutschka, PJ | 1 |
Achour, E; Azar, N; Belanger, C; Cassoux, N; Delattre, JY; Gerber, S; Hoang-Xuan, K; Leblond, V; Levy, V; Ribrag, V; Soussain, C; Suzan, F | 1 |
Bieri, S; Chapuis, B; Helg, C; Miralbell, R | 1 |
Inagawa, H; Kami, M; Kawagoe, S; Kishi, Y; Machida, U; Matsumura, T; Matsushita, H; Miyakoshi, S; Miyazaki, M; Mori, M; Morinaga, S; Muto, Y; Ueyama, J | 1 |
Bilgrami, SA; Bona, RD; Clive, J; Edwards, RL; Feingold, JM; Naqvi, B; Tutschka, PJ | 1 |
Andresen, S; Bolwell, B; Goormastic, M; Kalaycio, M; Kuczkowski, E; McBee, M; Pohlman, B; Sobecks, R; Wise, K | 1 |
Creutzig, U; de Vries, E; Hählen, K; Huismans, DR; Janka-Schaub, GE; Jansen, G; Kaspers, GJ; Peters, GJ; Pieters, R; Rots, MG; van Zantwijk, CH; Veerman, AJ; Zwaan, CM | 1 |
Aulagner, G; Bertrand, Y; Bleyzac, N; Dai, Q; Galambrun, C; Janoly, A; Jelliffe, RW; Magron, P; Maire, P; Martin, P; Souillet, G | 1 |
Arcese, W; Cerretti, R; De Felice, L; Donato, V; Fenu, S; Guglielmi, C; Iori, A; Laurenti, L; Mengarelli, A; Micozzi, A; Romano, A; Torromeo, C | 1 |
Thigpen, T | 1 |
Case, D; Damon, LE; Linker, CA; Navarro, WA; Ries, CA; Wolf, JL | 1 |
Birkmann, J; Bornhäuser, M; Ehninger, G; Fiedler, F; Hänel, A; Hänel, M; Hoffknecht, MM; Kröger, N; Kroschinsky, F; Krüger, W; Metzner, B; Schmid, B; Sonnenberg, S; Zander, AR | 1 |
Arai, T; Hanada, R; Ida, K; Inatomi, J; Kawaguchi, H; Kikuchi, A; Kishimoto, H; Oh-Ishi, T; Taketani, T; Yamamoto, K | 1 |
Al-Jefri, A; Al-Mahr, M; Ayas, M; Belgaumi, A; Leung, W; Solh, H | 1 |
Armata, J; Balcerska, A; Bogusławska-Jaworska, J; Boruczkowski, D; Bubała, H; Chybicka, A; Cwiklińska, M; Hicke, A; Kaczmarek-Kanold, M; Kałwak, K; Kolecki, P; Kowalczyk, J; Krauze, A; Matysiak, M; Płoszyńska, A; Rokicka-Milewska, R; Sikorska-Fic, B; Sońta-Jakimczyk, D; Staszak-Kowalska, R; Tomaszewska, R; Turkiewicz, D; Wachowiak, J; Wiśniewska-Slusarz, H; Wysocki, M | 1 |
Cavenagh, J; Chopra, R; Clark, FJ; Culligan, D; Davies, A; Fuller, S; Hunt, L; Hunter, A; Littlewood, T; Lush, R; Marks, DI; Marsh, J; Milligan, DW; Parker, A; Schey, S; Smith, GM; Towlson, K; Vandenberghe, E; Williams, CD; Yin, J | 1 |
Grigg, AP; Ritchie, DS; Roberts, AW; Shuttleworth, P; Szer, J | 1 |
Fedier, A; Fink, D; Haller, U; Lenherr, L; Schwarz, VA; Steiner, RA | 1 |
Cogle, CR; Finiewicz, KJ; Khan, SA; Leather, HL; Moreb, JS; Reddy, VS; Wingard, JR | 1 |
Fujii, S; Fujino, H; Hino, M; Hirai, M; Inoue, T; Sako, M; Teshima, H; Yagi, T | 1 |
Fouillard, L; Frassoni, F; Gorin, NC; Labopin, M; Meloni, G; Polge, E | 1 |
Hoang-Xuan, K; Levy, V; Soussain, C | 1 |
Becker, E; Casper, J; Franke, A; Freund, M; Heim, M; Jentsch-Ullrich, K; Koenigsmann, M; Mohren, M | 1 |
Andresen, S; Ball, E; Bolwell, B; Cook, D; Kalaycio, M; Kuczkowski, E; Pohlman, B; Rybicki, L; Sobecks, R | 1 |
Avalos, BR; Blum, W; Bolwell, BJ; Byrd, JC; Copelan, E; Elder, PJ; Farag, SS; Kalaycio, M; Lin, T; Marcucci, G; Penza, S; Pohlman, B; Sobecks, R | 1 |
Rao, PS | 1 |
Behringer, D; Bertz, H; Finke, J; Küttler, T; Samek, E; Spyridonidis, A; Wäsch, R; Waterhouse, M | 1 |
Alapetite, C; Anract, P; Babinet, A; Barthier, S; de Pinieux, G; Laurence, V; Palangié, T; Pierga, JY; Pouillart, P | 1 |
Al-Jefri, A; Al-Mahr, M; Al-Seraihi, A; Ayas, M; Belgaumi, A; El-Solh, H; Elhassan, I | 1 |
Driver, D; Kilby, AM; McTiernan, A; Michelagnoli, MP; Whelan, JS | 1 |
Aggarwal, C; Carabasi, MH; Gupta, S; Katz, RO; Nance, AG; Salzman, DE; Saylors, GB; Tilden, AB; Vaughan, WP | 1 |
Avalos, B; Benson, DM; Blum, W; Copelan, E; Elder, PJ; Farag, SS; Lin, TS; Penza, S | 1 |
Chantry, AD; Craddock, C; Craig, JI; Marks, DI; Orchard, K; Pearce, RM; Peggs, K; Roddie, C; Snowden, JA; Towlson, KE | 1 |
Andrèsen, S; Avalos, B; Bolwell, B; Copelan, E; Elder, P; Farag, S; Kalaycio, M; Lin, T; Marcucci, G; Penza, S; Pohlman, B; Sobecks, R; Wadehra, N | 1 |
Ades, L; Attal, M; Bernard, M; Blaise, D; Bordigoni, P; Bourhis, JH; Cassuto, JP; Chevalier, P; Deconinck, E; Facon, T; Garban, F; Ifrah, N; Kuentz, M; Lioure, B; Michallet, M; Milpied, N; Porcher, R; Renaud, M; Socié, G; Tabrizi, R; Tilly, H; Vernant, JP; Vigouroux, S | 1 |
Andresen, S; Bolwell, BJ; Brown, S; Dean, R; Hsi, ED; Kalaycio, M; Pohlman, B; Rybicki, LA; Smith, SD; Sobecks, R; Sweetenham, JW | 1 |
Flowers, C; Hutcherson, D; Langston, A; Santos, EC; Sessions, J; Waller, EK | 1 |
Bae, SH; Chae, YS; Eom, HS; Jung, JS; Kim, DH; Kim, HJ; Kim, JG; Kim, SJ; Kim, WS; Lee, JJ; Shin, HJ; Sohn, SK; Suh, C; Yang, DH | 1 |
Fujioka, K; Funabiki, T; Goto, H; Goto, S; Hanzawa, N; Ikuta, K; Izaki, S; Kai, S; Matsuda, M; Okuda, K; Sasaki, H; Sekiguchi, H; Sumita, H; Takahashi, H; Watanabe, Y; Yokota, S | 1 |
Casasnovas, O; Choquet, S; Dupriez, B; Fourme, E; Gisselbrecht, C; Hoang-Xuan, K; Jaccard, A; Janvier, M; Kolb, B; Leblond, V; Omuro, A; Sanson, M; Souleau, B; Soussain, C; Taillandier, L; Taksin, AL; Witz, F; Zini, JM | 1 |
Baer, MR; Baldus, CD; Bloomfield, CD; Caligiuri, MA; Carroll, AJ; Kolitz, JE; Langer, C; Larson, RA; Maharry, K; Marcucci, G; Mrózek, K; Paschka, P; Powell, BL; Ruppert, AS; Whitman, SP; Zhao, W | 1 |
Amoroso, L; Benhamou, E; Cacchione, A; Couanet, DV; Hartmann, O; LeMaitre, A; Simonnard, N | 1 |
Bai, CH; Kim, YD; Song, SY; Woo, HJ | 1 |
Acebo, E; Díaz-Pérez, JL; García-Ruiz, JC; Izu, R; Martínez de Lagrán, Z; Pérez-Barrio, S | 1 |
Bensinger, WI; Gooley, T; Gopal, AK; Holmberg, L; Maloney, D; Press, O; Zaucha, R | 1 |
Choi, YH; Huh, J; Jang, G; Kang, BW; Kim, C; Kim, S; Kim, SW; Kim, WS; Lee, DH; Lee, JS; Lee, SS; Ryu, JS; Suh, C | 1 |
Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P | 1 |
Andresen, S; Bolwell, BJ; Copelan, EA; Curtis, J; Dean, RM; Kalaycio, ME; Pohlman, B; Rybicki, LA; Smith, SD; Sobecks, RM; Sweetenham, JW | 1 |
Forman, SJ; Karanes, C; Kogut, N; Krishnan, AY; Nademanee, A; Nakamura, R; O'Donnell, M; Palmer, JM; Parker, P; Pullarkat, V; Rodriguez, R; Rosenthal, J; Senitzer, D; Shayani, S; Smith, E; Snyder, D | 1 |
Choi, DR; Huh, J; Kim, S; Kim, SW; Lee, DH; Lee, JS; Lee, SW; Sohn, BS; Suh, C; Yoon, DH | 1 |
Arai, S; Blume, K; Brown, J; Johnston, L; Laport, G; Lowsky, R; Miklos, D; Naik, S; Negrin, R; Shizuru, J; Wong, R | 1 |
Huh, J; Kim, JE; Kim, S; Kim, SW; Lee, DH; Lee, JS; Park, CJ; Suh, C; Yoo, C | 1 |
Esiashvili, N; Flowers, C; Kahn, S; Xu, Z | 1 |
Alberghini, M; Alvegard, TA; Bacci, G; Barbieri, E; Brach Del Prever, A; Capanna, R; Carli, M; Fagioli, F; Ferrari, S; Gandola, L; Luksch, R; Mapelli, S; Mercuri, M; Picci, P; Prete, A; Smeland, S; Sundby Hall, K; Tamburini, A; Tienghi, A; Wiebe, T | 1 |
Alvarnas, JC; Dagis, AC; Forman, SJ; Nademanee, AP; O'Donnell, MR; Parker, PM; Pullarkat, VA; Snyder, DS; Spielberger, RT; Stein, AS; Synold, TW; Thomas, SH; Tsirunyan, A; Wong, JY | 1 |
Anson, J; Gollard, RP; Khoury, J; Mason, J; Rosen, L | 1 |
Choma, M; Chybicka, A; Cornish, J; Gorczyńska, E; Grund, G; Kowalczyk, JR; Peters, C; Sykora, KW; Wachowiak, J | 1 |
Fanti, PA; Misciali, C; Miteva, M; Romanelli, P; Tosti, A; Vincenzi, C | 1 |
Choquet, S; del Rio, MS; Fourme, E; Glaisner, S; Hoang-Xuan, K; Janvier, M; Soussain, C | 1 |
Belinka, BA; Gupta, A; Kachlany, SC; Le, A | 1 |
Delioukina, M; Forman, SJ; Gaal, K; Kogut, N; Nademanee, A; O'Donnell, M; Palmer, JM; Popplewell, L; Senitzer, D; Thomas, S; Tsai, NC; Zain, J | 1 |
Boos, J; Hempel, G; Kersting, G; Lippert, J; Willmann, S; Würthwein, G | 1 |
Bahlis, NJ; Carlson, L; Duan, Q; Duggan, P; Hasegawa, W; Russell, JA; Stewart, DA; Voralia, M | 1 |
Bargetzi, M; Cornelissen, JJ; Ferrant, A; Fey, MF; Gratwohl, A; Graux, C; Huijgens, PC; Löwenberg, B; Maertens, J; Ossenkoppele, GJ; Schaafsma, R; Schanz, U; Schouten, HC; Theobald, M; van Putten, W; Vellenga, E; Verdonck, LF | 1 |
Al-Ahmari, A; Al-Jefri, A; Al-Nounou, R; Al-Seraihy, A; Ayas, M; Belgaumi, A; El-Solh, H | 1 |
Furuya, T; Ikeda, T; Inoue, M; Kaneda, H; Koshinaga, T; Maebayashi, T; Masuko, T; Mugishima, H; Ohashi, K; Sugito, K; Yagasaki, H | 1 |
Ali, Z; Dada, MO; Flowers, CR; Graiser, M; Hutcherson, DA; McMillan, S; Waller, EK; Zhang, H | 1 |
Forman, S; Liu, A; Palmer, J; Radany, E; Rosenthal, J; Schultheiss, T; Somlo, G; Stein, A; Wong, JY | 1 |
Abate, ME; Barbieri, E; Bisogno, G; Daolio, P; Eriksson, M; Fagioli, F; Ferrari, S; Gandola, L; Grignani, G; Hall, KS; Lindholm, P; Luksch, R; Picci, P; Podda, M; Prete, A; Ruggieri, P; Smeland, S; Tamburini, A; Tienghi, A | 1 |
Alimoghaddam, K; Bahar, B; Behfar, M; Ghavamzadeh, A; Hamdi, A; Hamidieh, AA; Iravani, M; Jahani, M; Jalali, A; Jalili, M; Mousavi, SA | 1 |
Ahmed, AB; Bruserud, O; Hatfield, KJ; Kittang, AO; Reikvam, H; Sjo, M; Tvedt, TH | 1 |
Boldrini, R; Castellano, A; Contoli, B; Corneli, T; Crocoli, A; DE Ioris, MA; DE Pasquale, MD; DE Sio, L; Garganese, MC; Jenkner, A; Pessolano, R; Serra, A | 1 |
Fan, ZP; Huang, F; Jiang, QL; Liu, QF; Meng, FY; Sun, J; Wei, YQ; Wu, MQ; Wu, XL; Xu, D; Yu, GP; Zhang, Y; Zhao, J | 1 |
Ahn, JS; Chae, YS; Jung, SH; Kim, HJ; Kim, YK; Kwak, JY; Lee, JJ; Lee, SR; Sohn, SK; Yang, DH; Yhim, HY | 1 |
Du, J; Fan, JL; Fu, WJ; Hou, J; Jiang, H; Jin, LN; Li, R; Xi, H; Zeng, TM; Zhang, CY; Zhou, LL | 1 |
Andreadis, C; Giacomini, KM; Kubo, M; Matsuda, K; Mefford, JA; Percival, ME; Singh, N; Stecula, A; Takahashi, A; Witte, JS; Yang, K; Yee, SW | 1 |
Akashi, K; Eto, T; Gondo, H; Harada, M; Kamimura, T; Miyamoto, T; Nagafuji, K; Ohno, Y; Takamatsu, Y; Takase, K; Taniguchi, S; Teshima, T | 1 |
Balleisen, L; Basara, N; Behre, G; Casper, J; Christopeit, M; Ganser, A; Hinke, A; Hinke, R; Kahl, C; Koenigsmann, M; Metzner, B; Mohren, M; Niederwieser, D; Reichle, A; Sayer, HG; Stadler, M; Theurich, S; Uharek, L | 1 |
Chung, JS; Kim, H; Kim, JS; Lee, GW; Lee, HS; Lee, WS; Shin, HJ; Song, MK; Yhim, HY | 1 |
Bubalo, J; Carpenter, PA; Leather, HL; Majhail, N; Marks, DI; Perales, MA; Pidala, J; Savani, BN; Shaughnessy, P; Wingard, J | 1 |
Forman, SJ; Kim, JH; Liu, A; Palmer, J; Rosenthal, J; Schultheiss, TE; Stein, A; Tsai, N; Wong, JY | 1 |
Akpek, G; Aljurf, M; Artz, A; Bredeson, CN; Chen, YB; Cooke, KR; Ho, VT; Lane, AA; Lazarus, HM; Logan, B; McCarthy, P; Olsson, R; Pasquini, MC; Saber, W; Zhu, X | 1 |
Ai, WZ; Andreadis, C; Benet, LZ; Damon, LE; Gaensler, KM; Kaplan, LD; Koplowicz, YB; Linker, CA; Logan, AC; Mannis, GN; Martin, TG; Olin, RL; Sayre, PH; Smith, CC; Sudhindra, A; Venstrom, JM; Wolf, JL | 1 |
Arnold, R; Ayuk, F; Beelen, D; Bethge, W; Bornhäuser, M; Gökbuget, N; Heinzelmann, M; Hölzer, D; Kobbe, G; Kröger, N; Martin, H; Meyer, RG; Pichlmeier, U; Schmid, C; Stelljes, M; Trenschel, R; Wolschke, C; Zander, A | 1 |
Elborai, Y; Elhaddad, A; Hafez, H; Hammad, M; Hussein, H; Lehmann, L; Moussa, EA | 1 |
Aplenc, R; Bagatell, R; Desai, AV; Fisher, BT; Getz, K; Huang, V; Li, Y; Mante, A; Seif, AE | 1 |
Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF | 1 |
Bagatell, R; Bunin, NJ; Desai, AV; Grupp, SA; Heneghan, MB; Li, Y; Seif, AE | 1 |
Andresen, S; Bolwell, BJ; Carlstrom, KD; Dean, R; Gerds, A; Hamilton, B; Hill, BT; Jagadeesh, D; Kalaycio, M; Liu, H; Majhail, NS; Pohlman, B; Rybicki, L; Sobecks, R | 1 |
Bruno, B; Chalandon, Y; Charbonnier, A; Coiteux, V; Simon, N; Souchet, L; Taque, S; Vincent, L; Yakoub-Agha, I | 1 |
Boddy, AV; Chatelut, E; Osborne, C; Paci, A; Veal, GJ; White-Koning, M | 1 |
Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Kebriaei, P; Ma, J; Milgrom, S; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shpall, EJ; Thall, PF; Timmons, M; Valdez, BC | 1 |
Aplenc, R; Bagatell, R; Desai, AV; Fisher, B; Getz, K; Huang, V; Li, Y; Seif, AE | 1 |
Baker, KS; Carpenter, PA; El-Haddad, A; Elzembely, MM; Park, JR; Pinto, N; Riad, KF; Sayed, HA | 1 |
Chen, J; Huang, H; Jiang, Y; Jin, Z; Liu, S; Ruan, J; Wu, D; Xiao, X; Zhang, L; Zhang, X | 1 |
Abounader, D; Andritsos, L; Benson, DM; Bolwell, B; Dean, R; Devine, SM; Efebera, YA; Elder, P; Hill, B; Hofmeister, CC; Jagadeesh, D; Jaglowski, S; Kalaycio, M; Majhail, NS; Penza, S; Pohlman, B; Rosko, A; Sharma, N; Singer, S; Sobecks, R; Vasu, S; William, BM; Zhao, Q | 1 |
Hong, JY; Huh, J; Hyung, J; Kim, JH; Kim, S; Lee, SW; Park, CS; Park, JS; Ryu, JS; Suh, C; Yoon, DH | 1 |
Anderton, J; Brennan, B; Evans, A; Fenwick, N; Fernández-Pinto, M; Gaspar, N; Gelderblom, H; Kaiser, S; Laurence, V; Marec-Bérard, P; Martín-Broto, J; Moroz, V; Owens, C; Sastre, A; Strauss, S; Wheatley, K; Whelan, J | 1 |
Cho, SH; Chung, JS; Jo, JC; Kim, DY; Shin, HJ | 1 |
Eich, HT; Scobioala, S | 1 |
Bae, SH; Choi, Y; Jo, JC; Kim, IH; Kim, JS; Lee, JH; Lee, SM; Lee, WS; Lee, YJ; Lim, SN; Yoon, SS | 1 |
Arakawa, Y; Hiwatari, M; Hogetsu, K; Kato, S; Koh, K; Kubota, Y; Takita, J; Watanabe, K | 1 |
Aleinikova, O; Ansari, M; Ariffin, H; Bader, P; Balduzzi, A; Bierings, M; Buechner, J; Burkhardt, B; Corbacioglu, S; Dalle, JH; Diaz-de-Heredia, C; Essa, M; Güngör, T; Ifversen, M; Lankester, A; Locatelli, F; Meisel, R; Peters, C; Pichler, H; Poetschger, U; Schrappe, M; Schultz, K; Sedlacek, P; Shaw, PJ; Staciuk, R; Stein, J; Svec, P; Toporski, J; Truong, TH; Vettenranta, K; von Stackelberg, A | 1 |
Bas, EG; Celen, S; Daloglu, H; Hazar, V; Kabakci, C; Karasu, GT; Pashayev, D; Pehlivan, B; Uygun, V; Yalcin, K; Yesilipek, A; Zhumatayev, S | 1 |
de Lima, VCC; Filho, JS; Germano, JN; Matias Vieira, GM; Moura, FL; Sapelli, J | 1 |
Chen, J; Fan, S; Jiang, F; Liu, X; Liu, Z; Sun, Y; Xiao, J | 1 |
Barnett, S; Bérénos, IM; Carruthers, V; Huitema, ADR; Kong, J; Lalmohamed, A; Nijstad, AL; Parke, E; Tweddle, DA; Veal, GJ; Zwaan, CM | 1 |
Do, YR; Kang, HJ; Kim, HG; Kim, KH; Kim, WS; Kong, JH; Kwak, JY; Lee, JH; Lee, M; Mun, YC; Oh, SY; Park, MR; Park, SK; Park, Y; Shin, HJ; Won, JH; Yang, DH | 1 |
Abraham, J; Agbetiafa, K; Ahle, G; Bonmati, C; Bouabdallah, K; Bouabdallah, R; Bourget, P; Casasnovas, O; Charron, C; Chauchet, A; Chinot, O; Choquet, S; Cornillon, J; Damaj, G; Delwail, V; Dorvaux, V; Fabbro, M; Fornecker, LM; Ghesquières, H; Giordan, Q; Gressin, R; Gyan, E; Hoang-Xuan, K; Houillier, C; Houot, R; Jabeur, W; Jardin, F; Le Garff-Tavernier, M; Malaise, D; Marolleau, JP; Moluçon-Chabrot, C; Morschhauser, F; Nichelli, L; Oberic, L; Peyrade, F; Plessier, A; Roland, V; Schenone, L; Schmitt, A; Soussain, C; Taillandier, L; Tanguy, ML; Tempescul, A; Thieblemont, C; Touitou, V; Ursu, R; Wantz-Mézières, S; Waultier-Rascalou, A; Willems, L | 1 |
Bauer, S; Baumhoer, D; Bernkopf, M; Bhadri, V; Bonar, F; Bovee, J; Brichard, B; Burdach, S; Butterfaß-Bahloul, T; Collaud, S; Cyprova, S; Dhooge, C; Dirksen, U; Egerer, G; Eich, HT; Ek, T; Faldum, A; Gelderblom, H; Hardes, J; Hartmann, W; Hassenpflug, W; Hauser, P; Haveman, L; Hjorth, L; Hong, A; Jürgens, H; Kanerva, J; Kessler, T; Kiss, J; Koch, R; Kruseova, J; Kühne, T; Metzler, M; Paulussen, M; Raciborska, A; Ranft, A; Rascon, J; Reichardt, P; Renard, M; Timmermann, B; van den Berg, H; Vieth, V | 1 |
Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
Albert, MH; Bader, P; Basu, O; Beier, R; Burkhardt, B; Classen, CF; Claviez, A; Corbacioglu, S; Deubzer, HE; Eichinger, A; Glogova, E; Greil, J; Gruhn, B; Güngör, T; Kafa, K; Kühl, JS; Lang, P; Lange, BS; Meisel, R; Müller, I; Peters, C; Poetschger, U; Sauer, MG; Schlegel, PG; Schulz, A; Stachel, D; Strahm, B; Wawer, A | 1 |
Brennan, B; Fenwick, N; Gaspar, N; Gelderblom, H; Kirton, L; Laurence, V; Marec-Bérard, P; Martín-Broto, J; Moroz, V; Owens, C; Sastre, A; Strauss, S; Wheatley, K; Whelan, J | 1 |
Arcese, W; Ciceri, F; Gedde-Dahl, T; Gorin, NC; Labopin, M; Lanza, F; Maertens, J; Meijer, E; Mohty, M; Montoro, J; Pabst, T; Pérez-Simón, JA; Sanz, J; Schaap, N; Van Gorkom, G; Versluis, J; Vrhovac, R | 1 |
Reviews
15 review(s) available for etoposide and busulfan
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Conditioning regimens for allogeneic bone marrow transplantation.
Topics: Anemia, Aplastic; Antilymphocyte Serum; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Etoposide; Humans; Leukemia; Lymphocyte Depletion; Melphalan; T-Lymphocytes; Transplantation, Homologous; Whole-Body Irradiation | 1992 |
[Allogeneic bone marrow transplantation in myeloid leukemia: chemical conditioning, clinical course and results].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Graft Enhancement, Immunologic; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Transplantation, Homologous | 1992 |
Use of busulfan containing chemotherapy for conditioning patients with leukemia for bone marrow allografting.
Topics: Actuarial Analysis; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytokines; Etoposide; Graft vs Host Disease; Humans; Leukemia; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Syndrome; Treatment Outcome; Whole-Body Irradiation | 1993 |
High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carboplatin; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Taxoids; Thiotepa | 1995 |
[Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia].
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Component Removal; Busulfan; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fusion Proteins, bcr-abl; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Ifosfamide; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 1998 |
Cancer chemotherapy in the elderly.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Busulfan; Daunorubicin; Doxorubicin; Etoposide; Female; Fluorouracil; Heart; Hematologic Neoplasms; Humans; Lung; Male; Middle Aged; Neoplasms; Pyrazoles | 1998 |
Pharmacokinetically guided administration of chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan; Carboplatin; Cisplatin; Etoposide; Fluorouracil; Humans; Topotecan | 2000 |
The role of gemcitabine-based doublets in the management of ovarian carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 2002 |
Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Carmustine; Cisplatin; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Life Tables; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prognosis; Retrospective Studies; Risk Factors; Sarcoma, Ewing; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2005 |
High-dose etoposide in allogeneic stem cell transplantation.
Topics: Adenine Nucleotides; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Busulfan; Carboplatin; Carmustine; Clinical Trials as Topic; Clofarabine; Cyclophosphamide; Dose Fractionation, Radiation; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Leukemia; Leukemia, Myeloid, Acute; Lomustine; Mucositis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy, Adjuvant; Severity of Illness Index; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2012 |
Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee.
Topics: Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Dosage Calculations; Etoposide; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Myeloablative Agonists; Obesity; Transplantation Conditioning | 2014 |
[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-T
Topics: Adult; Age Factors; Busulfan; Child; Comorbidity; Cyclophosphamide; Etoposide; France; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Liver Diseases; Melphalan; Obesity; Renal Insufficiency, Chronic; Societies, Medical; Surveys and Questionnaires; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2017 |
Risk stratification of pulmonary toxicities in the combination of whole lung irradiation and high-dose chemotherapy for Ewing sarcoma patients with lung metastases: a review.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Combined Modality Therapy; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Drug Administration Schedule; Etoposide; Female; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Melphalan; Procedures and Techniques Utilization; Radiation Pneumonitis; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Respiratory Function Tests; Risk; Sarcoma, Ewing; Whole-Body Irradiation; Young Adult | 2020 |
Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Etoposide; Humans; Infant; Infant, Newborn | 2022 |
Trials
51 trial(s) available for etoposide and busulfan
Article | Year |
---|---|
[Autotransplantation in acute nonlymphoid leukemia].
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Remission Induction; Transplantation, Autologous | 1991 |
Busulphan versus combination chemotherapy for initial treatment of chronic granulocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects | 1986 |
Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Gastrointestinal Diseases; Hodgkin Disease; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Stomatitis | 1994 |
[High-dose busulfan, VP-16 and ACNU therapy with stem cell transplantation for the treatment of children with acute leukemia].
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Nimustine | 1993 |
Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Recurrence; Survival Analysis; Time Factors; Transplantation, Autologous | 1993 |
A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Prospective Studies; Remission Induction; Risk Factors; Whole-Body Irradiation | 1993 |
Can busulfan replace fractionated total body irradiation as conditioning regimen for allogeneic bone marrow transplantation in children with acute lymphoblastic leukemia.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Rate; Whole-Body Irradiation | 1995 |
Etoposide with/without G-CSF with busulfan and cyclophosphamide as conditioning for bone marrow transplantation. The BMT Team.
Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Drug Administration Schedule; Drug Synergism; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hepatic Veno-Occlusive Disease; Humans; Hyperbilirubinemia; Immunologic Factors; Leukemia, Myeloid; Leukopenia; Male; Middle Aged; Premedication; Salvage Therapy | 1996 |
Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Prednisolone; Prognosis; Survival Rate; Transplantation, Autologous; Vincristine | 1996 |
Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.
Topics: Adult; Bone Marrow; Breast Neoplasms; Busulfan; Carboplatin; Carmustine; Cyclophosphamide; Drug Administration Schedule; Drug Synergism; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Interleukin-3; Leukapheresis; Leukemia; Leukocyte Count; Lymphoma; Male; Middle Aged; Neutrophils; Prospective Studies; Thiotepa; Whole-Body Irradiation | 1996 |
Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Prognosis; Proportional Hazards Models; Remission Induction; Survival Rate; Time Factors; Transplantation, Autologous | 1996 |
Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunosuppressive Agents; Life Tables; Lung Diseases, Interstitial; Male; Middle Aged; Neutropenia; Remission Induction; Treatment Outcome | 1996 |
Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Carmustine; Cause of Death; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 1997 |
Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukocyte Count; Life Tables; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Proportional Hazards Models; Prospective Studies; Remission Induction; Treatment Outcome | 1997 |
High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Transplantation, Autologous | 1998 |
High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Male; Methotrexate; Methylprednisolone; Middle Aged; Remission Induction; Time Factors; Transplantation, Homologous | 1997 |
Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Neuroblastoma; Prognosis; Rhabdomyosarcoma; Sarcoma, Ewing; Thiotepa | 1999 |
Autologous stem cell transplantation for acute myeloid leukemia in first remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytapheresis; Cytarabine; Cytogenetics; Disease-Free Survival; Etoposide; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukocyte Count; Middle Aged; Recurrence; Survival Rate; Transplantation, Autologous | 2000 |
Plasma antioxidant status after high-dose chemotherapy: a randomized trial of parenteral nutrition in bone marrow transplantation patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Ascorbic Acid; Bone Marrow Neoplasms; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Etoposide; Female; Glutathione; Glutathione Peroxidase; Humans; Male; Middle Aged; Parenteral Nutrition, Total; Vitamin E; Zinc | 2000 |
Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Survival Analysis; Transplantation, Autologous | 2000 |
Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): a phase I study of the Pediatric Blood and Marrow Transplant Consortium.
Topics: Adolescent; Alberta; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Missouri; Texas; Transplantation Conditioning; Treatment Outcome | 2000 |
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Eye Neoplasms; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Salvage Therapy; Thiotepa | 2001 |
Cytoreduction and stem cell mobilization with a regimen of paclitaxel, etoposide and cyclophosphamide followed by autologous transplantation using a preparative regimen of busulfan, etoposide and cyclophosphamide for patients with advanced lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis; Transplantation, Autologous | 2001 |
A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Mucous Membrane; Stomatitis; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2002 |
High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation.
Topics: Adult; Antineoplastic Agents, Alkylating; Busulfan; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Middle Aged; Recurrence; Stem Cell Transplantation; Transplantation, Autologous | 2004 |
CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; CD8-Positive T-Lymphocytes; Cyclophosphamide; Etoposide; Female; Graft Survival; Graft vs Host Disease; Histocompatibility; Histocompatibility Testing; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Salvage Therapy; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2005 |
High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2005 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Eye Neoplasms; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Survival Rate; Thiotepa | 2008 |
Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Male; Middle Aged; Secondary Prevention; Transplantation Conditioning; Transplantation, Autologous | 2010 |
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Pilot Projects; Radiation Dosage; Siblings; Sirolimus; Survival Analysis; Tacrolimus; Thrombotic Microangiopathies; Tissue Donors; Transplantation Conditioning; Vidarabine; Young Adult | 2010 |
Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Etoposide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Recurrence; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2011 |
BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Melphalan; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Sarcoma, Ewing; Vincristine; Young Adult | 2011 |
Phase-2 trial of an intensified conditioning regimen for allogeneic hematopoietic cell transplant for poor-risk leukemia.
Topics: Adult; Busulfan; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Recurrence; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation; Young Adult | 2011 |
Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematologic Neoplasms; Humans; Infant; Male; Melphalan; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Prospective Studies; Quality of Life; Rituximab; Survival Rate; Transplantation Conditioning; Vidarabine | 2011 |
Autologous peripheral blood stem cell transplantation for acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Prognosis; Prospective Studies; Remission Induction; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Liver; Male; Middle Aged; Organs at Risk; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy Dosage; Recurrence; Stomatitis; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation; Young Adult | 2013 |
Comparison of two different conditioning regimens before autologous transplantation for children with high-risk neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Gene Amplification; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Risk Factors; Thiotepa; Transplantation Conditioning | 2012 |
Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Disease Progression; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Prospective Studies; Recurrence; Risk Factors; Rituximab; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Young Adult | 2014 |
Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Blast Crisis; Bone Marrow; Busulfan; Child; Cyclophosphamide; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Melphalan; Middle Aged; Myelodysplastic Syndromes; Organ Sparing Treatments; Organs at Risk; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Radiotherapy Dosage; Recurrence; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2014 |
A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.
Topics: Administration, Intravesical; Adult; Area Under Curve; Busulfan; Disease-Free Survival; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Mucositis; Myeloablative Agonists; Recurrence; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2015 |
Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL).
Topics: Adolescent; Adult; Allografts; Busulfan; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Stem Cell Transplantation; Transplantation Conditioning | 2015 |
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Topics: Adult; Aged; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; North America; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2016 |
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Deoxycytidine; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Melphalan; Middle Aged; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Young Adult | 2018 |
International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Busulfan; Child; Child, Preschool; Consolidation Chemotherapy; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Induction Chemotherapy; Male; Middle Aged; Sarcoma, Ewing; Vincristine; Young Adult; Zoledronic Acid | 2020 |
Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma.
Topics: Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Busulfan; Combined Modality Therapy; Etoposide; Febrile Neutropenia; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Premedication; Progression-Free Survival; Prospective Studies; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2020 |
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoradiotherapy; Child; Child, Preschool; Equivalence Trials as Topic; Etoposide; Female; Follow-Up Studies; Humans; International Agencies; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Thiotepa; Vidarabine; Whole-Body Irradiation | 2021 |
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Mul
Topics: Antineoplastic Combined Chemotherapy Protocols; Behavior Therapy; Busulfan; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Transplantation, Autologous | 2023 |
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Consolidation Chemotherapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Male; Melphalan; Prospective Studies; Sarcoma, Ewing; Vincristine | 2022 |
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosphamide; Dactinomycin; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Ifosfamide; Melphalan; Sarcoma, Ewing; Vincristine | 2022 |
Other Studies
137 other study(ies) available for etoposide and busulfan
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Synthesis and induction of G0-G1 phase arrest with apoptosis of 3,5-dimethyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4(3H)-one.
Topics: Apoptosis; Azepines; G1 Phase; HL-60 Cells; Humans; K562 Cells; Molecular Structure; Pyrazoles; Resting Phase, Cell Cycle | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Second marrow transplantation following high dose busulfan, etoposide, and Ara-C after testicular relapse in a patient with AML].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Testicular Neoplasms | 1992 |
Relationships between oral mucositis and treatment variables in bone marrow transplant patients.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; District of Columbia; Etoposide; Female; Hospitals, University; Humans; Male; Middle Aged; Nursing Assessment; Pilot Projects; Risk Factors; Severity of Illness Index; Stomatitis; Whole-Body Irradiation | 1992 |
Treatment of infant leukemia with busulfan, cyclophosphamide +/- etoposide and bone marrow transplantation.
Topics: Bone Marrow Transplantation; Busulfan; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Graft vs Host Disease; Hematopoiesis; Humans; Incidence; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1992 |
Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Immunosuppressive Agents; Incidence; Leukemia; Middle Aged; Time Factors; Transplantation, Homologous | 1991 |
Influence of immunosuppression on acute liver toxicity after intensified conditioning regimens for bone marrow transplantation in children.
Topics: Bone Marrow Transplantation; Busulfan; Child; Cyclosporins; Drug Therapy, Combination; Etoposide; Graft vs Host Disease; Humans; Immunosuppression Therapy; Leukemia; Liver; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Transplantation, Autologous; Whole-Body Irradiation | 1991 |
Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Dose-Response Relationship, Drug; Etoposide; Female; Hodgkin Disease; Humans; Infusion Pumps; Lymphoma, Non-Hodgkin; Male; Middle Aged; Transplantation, Autologous | 1991 |
New conditioning regimens for high risk marrow transplants.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporins; Drug Evaluation; Etoposide; Graft vs Host Disease; Humans; Leukemia; Lymphoma; Middle Aged | 1989 |
Comparison of immunosuppressive agents for prevention of graft rejection in allogeneic bone marrow transplantation.
Topics: Animals; Bone Marrow Transplantation; Busulfan; Cytarabine; Etoposide; Graft Rejection; Immunosuppressive Agents; Postoperative Complications; Preoperative Care; Rats; Rats, Inbred Lew; Whole-Body Irradiation | 1989 |
Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Leukemia; Middle Aged; Whole-Body Irradiation | 1989 |
Comparison of cyclophosphamide, cytarabine, and etoposide as immunosuppressive agents before allogeneic bone marrow transplantation.
Topics: Animals; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Radiation; Etoposide; Graft Survival; Immunosuppression Therapy; Rats; Rats, Inbred Strains; Skin Transplantation; Whole-Body Irradiation | 1988 |
High dose busulfan/etoposide as a preparatory regimen for second bone marrow transplants in hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Etoposide; Follow-Up Studies; Humans; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Whole-Body Irradiation | 1987 |
[Postoperative therapy of epithelial ovarian cancer at the Göttingen University Gynecologic Clinic. A retrospective analysis of 82 patients 1981-1984].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Reoperation | 1986 |
Drug-induced histological changes in rat seminiferous tubular epithelium.
Topics: Animals; Antispermatogenic Agents; Busulfan; Cadmium; Epithelial Cells; Estradiol; Etoposide; Indenes; Male; Pyridines; Rats; Seminiferous Tubules; Testis | 1980 |
[Autologous bone marrow transplantation following high-dose busulfan and etoposide for a patient with non-Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lymphoma, Large-Cell, Immunoblastic; Male; Transplantation, Autologous | 1994 |
Severe esophageal stricture after autologous bone marrow transplant.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Esophageal Stenosis; Esophagitis; Etoposide; Fatal Outcome; Female; Humans; Immunocompromised Host; Leukemia, Myeloid; Melphalan; Middle Aged | 1995 |
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukapheresis; Lymphocyte Count; Lymphocyte Subsets; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Mesna; Middle Aged; Podophyllotoxin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Time Factors; Treatment Outcome; Vincristine | 1995 |
Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Humans; Leukemia; Lung; Lymphoma; Male; Middle Aged; Recurrence; Skin; Survival Rate; Transplantation, Autologous; Transplantation, Homologous | 1995 |
Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Karnofsky Performance Status; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Platelet Transfusion; Recurrence; Remission Induction; Survival Analysis; Thiotepa; Transplantation, Homologous; Whole-Body Irradiation | 1995 |
Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Busulfan; Carmustine; Cell Count; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoiesis; Hematopoietic Cell Growth Factors; Humans; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasms; Prognosis; Radiation Injuries; Treatment Outcome; Vincristine; Whole-Body Irradiation | 1995 |
[Excretion of beta-2-microglobulin and Tamm-Horsfall protein in patients undergoing a conditioning regimen before bone marrow transplantation].
Topics: Adjuvants, Immunologic; Adult; beta 2-Microglobulin; Bone Marrow Transplantation; Busulfan; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kidney Tubules; Male; Mucoproteins; Preoperative Care; Uromodulin | 1994 |
Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis.
Topics: Acute Disease; Adolescent; Adult; Blood Component Transfusion; Busulfan; Combined Modality Therapy; Etoposide; Female; Flow Cytometry; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Leukemia, Myeloid; Leukocyte Count; Leukopenia; Lymphocyte Subsets; Lymphoma; Male; Middle Aged; Nitrosourea Compounds; Platelet Count; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1994 |
Allogeneic bone marrow transplantation following busulfan-cyclophosphamide with or without etoposide conditioning regimen for patients with acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Cyclophosphamide; Etoposide; Female; Humans; Infant; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Premedication; Recurrence; Transplantation, Homologous | 1993 |
Busulfan-containing pre-transplant regimens for the treatment of solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasms; Ovarian Neoplasms; Pilot Projects; Retrospective Studies; Sarcoma | 1994 |
Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Chromatography, High Pressure Liquid; Drug Interactions; Etoposide; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Phenytoin; Therapeutic Equivalency | 1994 |
Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Infant; Leukemia; Lung Diseases, Interstitial; Lymphoma; Male; Middle Aged; Retrospective Studies; Skin Diseases; Whole-Body Irradiation | 1994 |
Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients.
Topics: Adolescent; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Child; Cyclophosphamide; Etoposide; Gastrointestinal Diseases; Hepatic Veno-Occlusive Disease; Humans; Hyperbilirubinemia; Incidence; Infusions, Intravenous; Kidney Diseases; Middle Aged; Pentoxifylline; Survival Analysis; Treatment Outcome; Tumor Necrosis Factor-alpha; Whole-Body Irradiation | 1993 |
Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Middle Aged; Premedication; Remission Induction; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 1993 |
Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Humans; Lymphoma; Middle Aged; Survival Analysis; Treatment Outcome | 1993 |
Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid; Recurrence; Survival Analysis; Time Factors; Transplantation, Autologous | 1993 |
Role of total body irradiation as based on the comparison of preparation regimens for allogeneic bone marrow transplantation for acute leukemia in first complete remission.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Humans; Infant; Japan; Leukemia; Male; Methotrexate; Nimustine; Proportional Hazards Models; Radiotherapy Dosage; Remission Induction; Transplantation, Homologous; Whole-Body Irradiation | 1993 |
Antitumor activity of treosulfan in human lung carcinomas.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Male; Mice; Mice, Nude; Mitomycin; Neoplasm Transplantation; Time Factors | 1996 |
Association of busulfan area under the curve with veno-occlusive disease following BMT.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Busulfan; Circadian Rhythm; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Hepatic Veno-Occlusive Disease; Humans; Male; Middle Aged; Retrospective Studies; Risk | 1996 |
Late relapse after autologous BMT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myelomonocytic, Acute; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Time Factors | 1996 |
Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Cells; Bone Marrow; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Life Tables; Middle Aged; Mitoxantrone; Recombinant Proteins; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thioguanine; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1996 |
Influence of graft-versus-host disease on outcome following allogeneic transplantation with radiation-free preparative therapy in patients with advanced leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Leukemia; Treatment Outcome | 1996 |
The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Evaluation Studies as Topic; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute | 1996 |
[High-dose chemotherapy with autologous stem cell rescue in patients with recurrent and high-risk pediatric brain tumors].
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Carboplatin; Child; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Risk Factors; Time Factors | 1997 |
Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation.
Topics: Adolescent; Adult; Anticoagulants; Antithrombin III; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infant; Life Tables; Male; Multiple Organ Failure; Neoplasms; Severity of Illness Index; Survival Analysis; Thrombophilia; Transplantation Conditioning; Treatment Outcome | 1997 |
Mobilization of Philadelphia-negative peripheral blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukaemia patients with a poor response to interferon-alpha.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon-alpha; Lenograstim; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Recombinant Proteins; Treatment Outcome | 1998 |
Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1998 |
Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survival; Etoposide; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Middle Aged; Transplantation, Autologous | 1998 |
High-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in children with high-risk NHL and ALL-preliminary results.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclosporine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Platelet Count; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Transplantation, Autologous; Treatment Outcome | 1998 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Leukemia, Myeloid; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neoplastic Stem Cells; Pilot Projects; Platelet Transfusion; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 1999 |
[Severe esophageal stenosis secondary to the administration of chemotherapy in a patient with acute myeloblastic leukemia].
Topics: Anti-Infective Agents; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dilatation; Esophageal Stenosis; Esophagitis; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Recurrence; Remission Induction; Transplantation Conditioning; Ulcer | 1999 |
Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation.
Topics: Allantoin; Antineoplastic Agents; Antioxidants; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Fatty Acids, Unsaturated; Hematologic Neoplasms; Humans; Iron; Lipid Peroxides; Oxidative Stress; Reactive Oxygen Species; Statistics, Nonparametric; Ubiquinone; Uric Acid; Whole-Body Irradiation | 2000 |
Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Evaluation; Etoposide; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid; Leukocytes; Male; Middle Aged; Recurrence; Survival Rate; Transplantation Conditioning; Treatment Outcome | 2000 |
High-dose chemotherapy with autologous stem cell support in an adult with bone marrow relapse of medulloblastoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Busulfan; Carboplatin; Cerebellar Neoplasms; Combined Modality Therapy; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Male; Medulloblastoma; Radiotherapy, Adjuvant; Remission Induction; Salvage Therapy; Thiotepa; Transplantation, Autologous | 2000 |
High-dose chemotherapy and autologous stem cell rescue for acute myeloid leukemia remains a safe, effective, and valid option.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Melphalan; Middle Aged; Platelet Count; Recombinant Proteins; Reproducibility of Results; Safety; Survival Rate; Transplantation, Autologous | 2000 |
A pilot study of busulfan, cyclophosphamide and etoposide followed by autologous transplantation for acute myeloid leukemia in remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Recurrence; Remission Induction; Transplantation, Autologous | 2000 |
Total body irradiation before allogeneic bone marrow transplantation: is more dose better?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2001 |
Systemic fusariosis after a preparative regimen including thiotepa, VP-16 and busulfan used for blood stem cell transplantation in Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Etoposide; Fatal Outcome; Fusarium; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Mycoses; Thiotepa; Transplantation Conditioning | 2001 |
Autologous peripheral blood progenitor cell transplantation for transformed diffuse large-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Transformation, Neoplastic; Cyclophosphamide; Disease-Free Survival; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Retrospective Studies; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2000 |
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
Topics: Amsacrine; Anthracyclines; Antineoplastic Agents; Busulfan; Cell Survival; Child; Child, Preschool; Cytarabine; Down Syndrome; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Thioguanine; Vincristine | 2002 |
Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Topics: Adolescent; Alkylating Agents; Area Under Curve; Bayes Theorem; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Genetic Diseases, Inborn; Graft Survival; Hematologic Neoplasms; Hepatic Veno-Occlusive Disease; Humans; Incidence; Infant; Life Tables; Male; Melphalan; Prospective Studies; Severe Combined Immunodeficiency; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2001 |
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Infant; Leukemia; Life Tables; Male; Methylprednisolone; Middle Aged; Premedication; Retrospective Studies; Risk; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2002 |
Autologous stem cell transplantation for advanced acute myeloid leukemia.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Count; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Cytogenetics; Disease-Free Survival; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Translocation, Genetic; Transplantation, Autologous | 2002 |
Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Autologous | 2002 |
Chronic active Epstein-Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Chronic Disease; Combined Modality Therapy; Cyclophosphamide; Epstein-Barr Virus Infections; Etoposide; Female; Herpesvirus 4, Human; Humans; Immunosuppressive Agents; In Situ Hybridization; Lymphoma; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous | 2002 |
Allogeneic BMT for infantile acute leukemia: what is the optimal conditioning regimen?
Topics: Acute Disease; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survival; Etoposide; Growth Disorders; Humans; Infant; Leukemia; Radiation Injuries; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Whole-Body Irradiation | 2002 |
[Results of treatment of children with chronic myelogenous leukaemia (CML) obtained by the Polish Paediatric Leukaemia/Lymphoma Study Group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Hydroxyurea; Infant; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mercaptopurine; Poland; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2000 |
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclosporine; Cytarabine; Data Collection; Etoposide; Female; Follow-Up Studies; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.
Topics: Animals; Antineoplastic Agents; BRCA1 Protein; Busulfan; Camptothecin; Cell Division; Cell Line; Doxorubicin; Etoposide; Fibroblasts; Gene Deletion; Genes, BRCA1; Mice; Mitoxantrone; Topotecan; Tumor Suppressor Protein p53 | 2003 |
Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Immunosuppression Therapy; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Platelet Count; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Time Factors; Transplantation, Autologous; Whole-Body Irradiation | 2003 |
Esophageal actinomycosis after allogeneic peripheral blood stem cell transplantation for extranodal natural killer/T cell lymphoma, nasal type.
Topics: Actinomycosis; Adult; Busulfan; Cyclophosphamide; Esophageal Diseases; Etoposide; Humans; Immunosuppressive Agents; Killer Cells, Natural; Lymphoma, T-Cell; Male; Peripheral Blood Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous | 2003 |
Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Female; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous | 2004 |
[Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Eye Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, T-Cell; Middle Aged; Prognosis; Recurrence; Thiotepa | 2004 |
Nephrotic syndrome in patients with peripheral blood stem cell transplant.
Topics: Acute Kidney Injury; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytomegalovirus Infections; Etoposide; Glomerulonephritis, Membranous; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Prednisone; Rituximab; Sepsis; Staphylococcal Infections; Tacrolimus; Transplantation Conditioning | 2005 |
Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin.
Topics: Adult; Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Cell Culture Techniques; Cell Proliferation; Cell Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Lewis X Antigen; Lipopolysaccharide Receptors; Lymphoma; Male; Microscopy, Fluorescence; Middle Aged; Myelodysplastic Syndromes; Nucleic Acid Synthesis Inhibitors; Stromal Cells; Transplantation Conditioning; Vidarabine | 2005 |
The outcome of children with acute myeloid leukemia (AML) post-allogeneic stem cell transplantation (SCT) is not improved by the addition of etoposide to the conditioning regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2006 |
High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Busulfan; Combined Modality Therapy; Disease Progression; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Neoplasm Recurrence, Local; Sarcoma, Ewing; Treatment Outcome | 2006 |
Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
Topics: Administration, Oral; Adolescent; Adult; Aged; Busulfan; Chi-Square Distribution; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myeloablative Agonists; Secondary Prevention; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2006 |
High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation, Autologous | 2007 |
Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Registries; Remission Induction; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; United Kingdom; Whole-Body Irradiation | 2006 |
Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Lung Diseases; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Tumor Burden | 2006 |
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Data Collection; Disease-Free Survival; Etoposide; Female; France; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2007 |
Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Autologous | 2007 |
Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation--a similar experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Drug Evaluation; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Longitudinal Studies; Male; Middle Aged; Transplantation, Autologous; Treatment Outcome | 2007 |
Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Transplantation Conditioning; Treatment Outcome | 2007 |
Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Infant; Leukemia; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Nimustine; Recurrence; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2007 |
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Busulfan; Cytarabine; Daunorubicin; Etoposide; Female; fms-Like Tyrosine Kinase 3; Genes, Wilms Tumor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nucleophosmin; Prognosis; Proportional Hazards Models; Statistics, Nonparametric | 2008 |
Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Busulfan; Carboplatin; Child; Child, Preschool; Clonazepam; Etoposide; Female; Hepatic Veno-Occlusive Disease; Humans; Infant; Male; Retrospective Studies; Risk Factors; Sarcoma; Seizures; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2008 |
Mucoepidermoid carcinoma of the submandibular gland after chemotherapy in a child.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Busulfan; Carcinoma, Mucoepidermoid; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Image Processing, Computer-Assisted; Leukemia, Myeloid, Acute; Male; Neck Dissection; Neoplasms, Second Primary; Positron-Emission Tomography; Submandibular Gland Neoplasms; Thioguanine; Tomography, X-Ray Computed; Transplantation Conditioning | 2009 |
[Autologous hematopoietic stem cell transplantation followed by oral bexarotene in a patient with advanced mycosis fungoides].
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Busulfan; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Interferon alpha-2; Interferon-alpha; Mechlorethamine; Methylprednisolone; Mycosis Fungoides; Peripheral Blood Stem Cell Transplantation; Prednisone; PUVA Therapy; Recombinant Proteins; Remission Induction; Tetrahydronaphthalenes; Transplantation, Autologous; Vincristine | 2008 |
High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Drug Evaluation; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Retrospective Studies; Thiotepa; Transplantation, Autologous | 2008 |
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Idarubicin; Immunosuppressive Agents; Leukemia; Leukemia, Myeloid, Acute; Male; Methylprednisolone; Mucositis; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Premedication; Retrospective Studies; Risk Factors; Semustine; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2009 |
Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Busulfan; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myeloablative Agonists; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2010 |
Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY.
Topics: Adult; Busulfan; Cyclophosphamide; Cytomegalovirus; Etoposide; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Transplantation Conditioning; Treatment Outcome; Virus Activation | 2011 |
Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Case-Control Studies; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Etoposide; Female; Hodgkin Disease; Humans; Male; Middle Aged; Radiotherapy; Secondary Prevention; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome; Tumor Burden; Young Adult | 2011 |
Intramedullary PNET of the spine: long-term survival after combined modality therapy and subsequent relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cerebellar Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Female; Humans; Methylprednisolone Hemisuccinate; Neuroectodermal Tumors, Primitive; Neuroprotective Agents; Radiotherapy; Spinal Neoplasms; Temozolomide; Thiotepa; Thoracic Vertebrae; Vincristine; Young Adult | 2011 |
Permanent alopecia after systemic chemotherapy: a clinicopathological study of 10 cases.
Topics: Alopecia; Antineoplastic Agents; Busulfan; Cisplatin; Dermis; Diagnosis, Differential; Docetaxel; Etoposide; Female; Hair; Humans; Male; Neoplasms; Taxoids | 2011 |
Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Cisplatin; Cytarabine; Dexamethasone; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Rituximab; Salvage Therapy; Thiotepa; Young Adult | 2011 |
In vitro synergism between LFA-1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Busulfan; Cell Line, Tumor; Daunorubicin; Drug Interactions; Drug Synergism; Etoposide; Exotoxins; Flow Cytometry; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia; Leukocytes; Lymphocyte Function-Associated Antigen-1; Membrane Potential, Mitochondrial; Mitoxantrone; Piperazines; Pyrimidines; Tumor Cells, Cultured | 2011 |
Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Disease Progression; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Radiotherapy; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2011 |
Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Child; Child, Preschool; Computer Simulation; Cyclophosphamide; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Etoposide; Female; Humans; Infant; Male; Melphalan; Metabolic Clearance Rate; Middle Aged; Models, Biological; Neoplasms; Protein Binding | 2012 |
Outcome of allogeneic stem cell transplantation with a conditioning regimen of busulfan, cyclophosphamide and low-dose etoposide for children with myelodysplastic syndrome.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Immunosuppressive Agents; Infant; Kaplan-Meier Estimate; Male; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2011 |
Application of high-dose rate (60)Co remote after-loading system for local recurrent neuroblastoma.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Busulfan; Carboplatin; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Male; Melphalan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Vidarabine; Vincristine | 2011 |
Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Cyclophosphamide; Drug Administration Routes; Etoposide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2012 |
Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Melphalan; Myeloablative Agonists; Neoplasm Metastasis; Prognosis; Sarcoma, Ewing; Stem Cell Transplantation; Vincristine; Young Adult | 2012 |
Non-TBI hematopoietic stem cell transplantation in pediatric AML patients: a single-center experience.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Myeloablative Agonists; Proportional Hazards Models; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2013 |
Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens.
Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Biphenotypic, Acute; Male; Middle Aged; Retrospective Studies; Standard of Care; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation; Young Adult | 2013 |
Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Humans; Induction Chemotherapy; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Mucositis; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2013 |
[Busulfan, cyclophosphamide and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma].
Topics: Adult; Busulfan; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2013 |
Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Busulfan; Chromosome Mapping; Cytarabine; Disease-Free Survival; DNA; Etoposide; Female; Follow-Up Studies; Genetic Loci; Genotype; Glutathione Transferase; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Membrane Transport Proteins; Middle Aged; Phenotype; Polymorphism, Single Nucleotide; Proportional Hazards Models; Remission Induction; Young Adult | 2013 |
Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Autografts; Busulfan; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Survival Rate; Transplantation Conditioning | 2013 |
Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2014 |
Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Registries; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Whole-Body Irradiation | 2015 |
Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers.
Topics: Adolescent; Antineoplastic Agents; Boston; Brain Neoplasms; Busulfan; Carboplatin; Child; Child, Preschool; Egypt; Etoposide; Humans; Infant; Infant, Newborn; Melphalan; Neuroblastoma; Retrospective Studies; Transplantation Conditioning; Treatment Outcome | 2016 |
Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Carboplatin; Child; Child, Preschool; Critical Care; Databases, Factual; Etoposide; Female; Follow-Up Studies; Humans; Incidence; Infant; Length of Stay; Male; Melphalan; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Sepsis; Stem Cells; Transplantation Conditioning; United States | 2016 |
Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Child; Child, Preschool; Cohort Studies; Etoposide; Female; Hepatic Veno-Occlusive Disease; Humans; Hypertension, Pulmonary; Infant; Kidney Diseases; Male; Melphalan; Mucositis; Myeloablative Agonists; Neuroblastoma; Pancytopenia; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Young Adult | 2016 |
Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Topics: Adult; Aged; Busulfan; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Liver Function Tests; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Respiratory Function Tests; Retrospective Studies; Transplantation, Autologous; Treatment Outcome; Young Adult | 2016 |
Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.
Topics: Adolescent; Age Factors; Antineoplastic Agents; Area Under Curve; Busulfan; Carboplatin; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Drug Dosage Calculations; Drug Monitoring; Etoposide; Humans; Infant; Models, Biological; Neoplasms; Patient Safety; Risk Factors | 2018 |
Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Carboplatin; Child; Child, Preschool; Databases, Factual; Etoposide; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Length of Stay; Male; Melphalan; Neuroblastoma; Stem Cell Transplantation | 2018 |
Acute Complications After High-Dose Chemotherapy and Stem-Cell Rescue in Pediatric Patients With High-Risk Neuroblastoma Treated in Countries With Different Resources.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Carboplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Egypt; Etoposide; Female; Humans; Male; Melphalan; Middle Aged; Neuroblastoma; Stem Cell Transplantation; Transplantation Conditioning | 2018 |
Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Semustine; Survival Rate; Transplantation Conditioning | 2019 |
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Young Adult | 2019 |
Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous System Neoplasms; Consolidation Chemotherapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphoma; Male; Middle Aged; Prospective Studies; Registries; Stem Cell Transplantation; Survival Rate; Thiotepa | 2019 |
Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL).
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Melphalan; Transplantation Conditioning; Transplantation, Autologous | 2020 |
Tandem high-dose chemotherapy with autologous stem cell rescue for stage M high-risk neuroblastoma: Experience using melphalan/etoposide/carboplatin and busulfan/melphalan regimens.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Child; Child, Preschool; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Neoplasm Staging; Neuroblastoma; Retrospective Studies; Transplantation, Autologous | 2020 |
Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Organophosphorus Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2021 |
BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2021 |
Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation with Cocktail Conditioning Regimen for the Treatment of Pediatric Patients with Chronic Active Epstein-Barr Virus: A Retrospective Observational Study.
Topics: Antilymphocyte Serum; Busulfan; Child; Cyclophosphamide; Cytarabine; Epstein-Barr Virus Infections; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; Humans; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous | 2022 |
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Central Nervous System; Central Nervous System Neoplasms; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Neoplasm Recurrence, Local; Prospective Studies; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2022 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |
Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial.
Topics: Busulfan; Child; Cyclophosphamide; Etoposide; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Neoplasms; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2022 |
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2023 |